AI Strategy Index

Roche AI Strategy: AI Independence in Research

How Roche uses AI on its own work: AI input in 40% of pipeline decisions, more than 3,500 GPUs and plans for autonomous AI labs. Updated November 2026.

Company
Roche
Industry
Healthcare & pharma
Headquarters
Basel, Switzerland
Region
Europe
AI strategy
Part of corporate strategy
Index group
STOXX Europe 50

Swiss healthcare company in pharmaceuticals and diagnostics, including Genentech in the US

Where the AI strategy is set out

Roche has no standalone AI strategy document. Its AI plans come from its September 2026 investor event and a March 2026 media release.

Read the company source

Where Roche Is Going with AI

Roche wants AI independence in research. Aviv Regev, Executive Vice President and Head of Genentech Research and Early Development, told investors in September 2026 that Roche is committed to “AI independence” in R&D, according to a Reuters report. Roche plans to move toward autonomous AI labs and has started building AI-driven labs.

Roche has no standalone AI strategy document. This profile draws on its September 2026 investor event, a March 2026 media release and news reports.

The focus has four parts.

  • Research: Lab-in-the-Loop, which links lab experiments with Roche’s AI models, and Target Nexus, an AI tool for research portfolio decisions
  • Manufacturing: digital twins of production lines that help engineers improve processes and factory designs
  • Diagnostics and pathology: accelerated computing for large diagnostic datasets and AI that scans pathology images for subtle disease patterns
  • Digital health: guardrails that keep conversational AI for patients safe and reliable
A scientist in safety glasses and blue gloves reaches for a sample tray in a lab
A Roche scientist at work, from its story on how AI and machine learning are changing drug discovery and patient care. Image: Roche

What It Takes: Own Compute, Lab-in-the-Loop and AI-Driven Labs

Roche runs its own AI compute at scale. In March 2026 it added 2,176 NVIDIA Blackwell GPUs in the US and Europe, which took its total across its own sites and the cloud above 3,500, according to its media release. Roche says this is the largest announced GPU footprint available to a pharmaceutical company.

Speed is the reason for the investment. Wafaa Mamilli, Chief Digital and Technology Officer, said in the release: “In healthcare, time is the most critical variable.”

Lab-in-the-Loop links experiments to AI models so scientists can test hypotheses at scale. Regev said Genentech has pioneered the approach for more than five years. Roche also opened a Boston innovation center that will focus partly on AI and machine learning in drug development.

Headcount held at about 103,000 from 2022 to 2024. Roche reported more than 100,000 employees for 2025, and the sources reviewed do not link its headcount to AI.

AI fluency, coded against the Lead with AI Fluency Matrix (September 2026 edition):

  • Fluency floor: Not published. Roche has set no public AI training requirement or usage standard for all staff.
  • Highest level evidenced: Level 3 (Integrating), company-claimed. AI contributed to 40% of pipeline decisions from late 2025 to mid-2026, Regev said. Autonomous AI labs would go further, and Roche has only started building them.
  • Portfolio design: Roche concentrates AI on research, backed by its own compute, and extends it to manufacturing, diagnostics and digital health.

How Roche Measures Results

Roche tracks how often AI shapes research decisions. The figures below are company-claimed:

  • Pipeline decisions: 40% of decisions from the fourth quarter of 2025 to the second quarter of 2026 had a tracked AI or computational contribution
  • Target Nexus: on track to contribute to 80% of research portfolio decisions by the end of 2026
  • Compute: more than 3,500 Blackwell GPUs across its own sites and the cloud

Gaps remain. Roche reports AI’s share of research decisions but no value in francs, and it publishes little on AI for its staff outside research. Closing both is the step from AI adoption to AI value.

Next markers: Target Nexus at 80% of research portfolio decisions, the first autonomous AI labs, an AI standard for all staff and an exact headcount for 2025.

Change log

  • March 2026: Roche expands its AI factory to more than 3,500 GPUs.
  • September 2026: Roche commits to AI independence in R&D and reports AI input in 40% of pipeline decisions.

The Bottom Line

  • Disclosure: 4 of 4. Roche answers all four questions, the last in part, with AI’s share of research decisions and no value figure.
  • AI independence in research is the goal.
  • Roche owns its compute, with more than 3,500 GPUs.
  • Level 3 is evidenced in research decisions, on company-claimed figures.
  • The say-do gap is people. AI shapes research decisions, but Roche publishes no AI standard for its wider workforce.
  • Watch Target Nexus. The test is whether AI reaches 80% of research portfolio decisions by the end of 2026.

Revenue, Headcount and Revenue per Employee

What the numbers show: Total revenues fell 5% from 2022 to 2024 while headcount held at about 103,000, so revenue per employee fell 5%, to about CHF 604k. Most of the fall came in 2023, when sales of Roche’s COVID-19 products dropped. These figures do not show that AI caused any change.

Revenue, headcount and revenue per employee, FY2022 to FY2024

  • FY2022: CHF 65.81bn revenue, 103,613 employees, CHF 635k per employee
  • FY2023: CHF 60.44bn revenue, 103,605 employees, CHF 583k per employee
  • FY2024: CHF 62.40bn revenue, 103,249 employees, CHF 604k per employee

Change, FY2022 to FY2024: revenue down 5%, headcount flat, revenue per employee down 5%.

Notes: Revenue is total revenues, as reported. Headcount is at year-end. Roche reports only more than 100,000 employees for 2025, so the series ends in 2024. Total revenues include sales plus royalties and other operating income, and were CHF 63.4bn in 2025. Trend figures stay in CHF so exchange-rate moves do not distort them. At the 2025 average exchange rate, latest revenue per employee is about $729k.

These figures give context on scale and productivity. They do not show that AI caused any change. Sources: Stock Analysis (S&P Global data) and Roche annual reports.

How Roche Compares with European Pharma Peers

We looked at how Roche compares with other European pharmaceutical companies in the index. Here is how they stack up.

CompanyDisclosureAI ownerFluency floorGovernanceAI value reportedRevenue per employee
AstraZeneca4 of 4No single owner named; finance picks pilots to scaleNot published; Silver certification above a set gradeFinance reviews which pilots scaleNo: certifications and pilots only$611k
GSK3 of 4SVP Global Head of AI and Machine LearningNot publishedLittle publishedNo: savings plan with no AI share$631k
Novartis2 of 4CIO; no Chief AI OfficerRole-based paths, no company-wide floorPublished, a standing board topicLinked to lower costs, no figure$725k
Novo Nordisk4 of 4CEO-led OpenAI partnershipNot published; OpenAI to build AI fluencyData governance and human oversight, statedResults by use case, no total$680k
Roche4 of 4Chief Digital and Technology Officer; research head leads research AINot publishedLittle publishedAI share of research decisions, no value$729k
Sanofi4 of 4Chief Digital OfficerLevel 1, about 80% useRAISE framework, five pillarsResults by use case, no total$644k

Disclosure counts how many of the four strategy questions (where it is going, where it will focus, what it will take and how it will know it is working) a company answers in public. Fluency floor is the lowest level of AI fluency a company expects of all its people, on the five levels of the Lead with AI Fluency Matrix: Avoiding (0), Chatting (1), Collaborating (2), Integrating (3) and Transforming (4). The other columns summarize each company’s profile. Revenue per employee is for each company’s latest fiscal year, in US dollars. See all companies in the AI Strategy Index.

Frequently Asked Questions

What is Roche’s AI strategy for its own work?

Roche wants AI independence in research and is moving toward autonomous AI labs. It also uses AI in manufacturing, diagnostics and digital health, a path that points toward an AI-native organization in R&D.

‍

Who leads AI at Roche?

Chief Digital and Technology Officer Wafaa Mamilli leads the AI factory, according to Roche’s March 2026 release. Aviv Regev, Head of Genentech Research and Early Development, set out the research plans in September 2026.

‍

What is Lab-in-the-Loop at Roche?

Lab-in-the-Loop links Roche’s lab experiments with its AI models. Scientists use it to test hypotheses at scale, and Genentech has used the approach for more than five years.

‍

Is Roche cutting jobs because of AI?

The sources reviewed do not link Roche’s headcount to AI. Headcount held at about 103,000 from 2022 to 2024.

‍

How is this profile put together?

Lead with AI profiles use public sources only, such as annual reports, earnings materials, filings and on-record interviews, dated at the time of writing. AI fluency is coded against the Lead with AI Fluency Matrix, and company figures are marked as company-claimed unless they have been independently verified.

About the AI Strategy Index

The Lead with AI AI Strategy Index profiles how the largest companies in the US and Europe approach AI, starting with the S&P 100 and the STOXX Europe 50. Each profile answers four questions: where the company is going with AI, where it will focus, what it will take and how it will know it is working. AI Pacesetters and notable companies outside the two indexes are profiled for contrast and are not counted. Profiles use public sources only, and AI fluency is coded against the Lead with AI Fluency Matrix.

See all company profiles